Working Groups

Active?
Facet Toggle

Working Group on a New Grand Bargain for Antimicrobial Procurement
Amanda Glassman
et al.
June 27, 2022
While there have been high-level commitments from the World Health Assembly, the United Nations General Assembly (UNGA), the G20, and the G7 to tackle AMR, there has yet to be a fundamental change in how we purchase antimicrobials, or an international approach to improving access, fostering innovati...
Working Group on New Evidence Tools for Policy Impact
Amanda Glassman
et al.
June 01, 2021
CGD recently launched a working group to consider how the next generation of investments in impact evaluations—as part of the broader evidence and data ecosystem—can enhance their usefulness, responsiveness, and relevance for public policy decision-making. A renewed agenda is needed to help increase...
Working Group on the Future of Global Health Procurement
Amanda Glassman
et al.
July 31, 2017
Many low-and lower-middle-income countries currently procure a large portion of their health commodities through centralized, donor-managed procurement mechanisms, and often at subsidized prices or as donations. Over the next several decades, however, the landscape of global health procurement will ...
Forced Displacement and Development Study Group
Cindy Huang
et al.
September 15, 2016
CGD and IRC are convening a joint study group to explore what a sound partnership framework between host governments and development and humanitarian actors might look like in protracted displacement scenarios. This effort is guided by a vision of displaced people having meaningful opportunities tha...
The Future of IDA Working Group
Alan Gelb
et al.
September 15, 2014
Drug Resistance Working Group (November 2007 – June 2010)
Amanda Glassman
and
Prashant Yadav
September 10, 2014
Development Impact Bond Working Group
Catalina Geib
et al.
August 25, 2014
Value for Money: An Agenda for Global Health Funding Agencies
Amanda Glassman
et al.
August 25, 2014
As international commitments become more ambitious and aid resources become increasingly constrained, global health funding agencies are seeking to improve the efficiency and impact of their investments. This growing “value for money” (VfM)  agenda aims to reduce costs, increase imp...